Nanobiotix’s Phase 1 trial in pancreatic cancer safe to proceed (FDA)
another step forward for NBTXR3 activated by radiation therapy
Pharmaceuticals, Biotechnology and Life Sciences
another step forward for NBTXR3 activated by radiation therapy
Nanobiotix has appointmented Alain Dostie, a senior executive from the pharmaceutical industry, as its Chief Operating Officer (COO).
Nanobiotixa has announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October.